ADAMTSL4-AS2

Across TCGA pan-cancer cohorts, ADAMTSL4-AS2 RNA differs between tumor and matched normal tissue in 11 of 18 cancer types tested, making tumor–normal expression one of ADAMTSL4-AS2’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where ADAMTSL4-AS2 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types ADAMTSL4-AS2 is over-expressed in tumor, although a few such as BRCA and LUSC show the opposite, repressed pattern.

KIRC, BRCA, and LUSC are the cancer types where ADAMTSL4-AS2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ADAMTSL4-AS2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	All	All	+0.411	<.001	9	view →
BRCA	All	III,IV	−1.116	<.001	8	view →
LUSC	All	II,III,IV	−1.418	<.001	6	view →
UCEC	All	All	−0.742	<.001	6	view →
LIHC	All	III,IV	+0.268	.014	5	view →
CHOL	All	All	+2.118	<.001	3	view →
BLCA	Female	All	−0.811	.010	3	view →
KICH	Female	All	−0.613	.017	3	view →
LUAD	All	All	−0.536	.006	2	view →
THCA	All	All	−0.372	.007	2	view →
COAD	Female	IV	+1.200	.046	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 11 strongest of 11 lineages.

ADAMTSL4-AS2–KIRC

Open the KIRC breakdown →